RESEARCH TRIANGLE PARK –Kymanox, a Morrisville life sciences professional services organization, has acquired a European company in a move that expands Kymanox’s reach in Europe.

The deal for anteris, comprised of Germany’s anteris medical GmbH and Swiss-based anteris helvetia AG, broadens both companies’ specialized services to life sciences clients, Kymanox said in announcing the acquisition earlier this month. Terms were not disclosed.

Kymanox provides engineering, scientific, regulatory and other support services to life sciences companies. Anteris helps life sciences companies develop and commercialize medical devices, in-vitro diagnostic products, and combination products, or those with two or more regulated components.

“We are excited about merging our capabilities with anteris, a nimble organization with an amazing reputation for being committed to their clients’ programs with a focus on results, which means getting critical treatments to patients-in-need,” said Kymanox founder and CEO Stephen Perry. “Furthermore, anteris’ physical presence in Germany and Switzerland, along with their strength and experience in biosimilars, fills two important strategic needs for Kymanox.”

The companies share important goals, including geographic expansion and broadening their specialized service offerings to life sciences organizations. The combination of the companies’ technical, scientific and regulatory expertise will benefit clients attempting to bring biologics to market in the United States and Europe, Kymanox said in its announcement.

The anteris acquisition comes less than two years after an eventful 2021 that saw Kymanox land a significant investment and acquire a drug delivery services provider.

The growth recapitalization investment from WestView Capital Partners, a Boston private equity firm, provided an undisclosed amount of funding to fuel Kymanox’s expansion. And the company’s acquisition of Neuma, based in King of Prussia, Pa., broadened Kymanox’s capabilities in complex drug delivery systems and medical device technologies.

Kymanox, founded in 2004, was recognized in 2022 as a Triangle Business Journal Life Sciences Award winner.

(C) N.C. Biotech Writer